Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Transmembrane protein 166
(
TMEM166
) is a lysosomal/endoplasmic reticulum-associated protein found in various species where it acts as a regulator of programmed cell death, mediating both autophagy and apoptosis. In the present study, we investigated the role of
TMEM166
following MCAO injury in rats to determine whether the structural damages following injury were orchestrated in part by
TMEM166
. One hundred and fifty six male Sprague-Dawley rats were randomly divided into 4 groups: Sham, MCAO, MCAO+control siRNA, MCAO+TMEM166 siRNA. Outcomes were measured including mortality rate, brain edema, BBB disruption, and neurobehavioral testing. Western blotting techniques measured the expression of key pro-autophagic and apoptotic proteins such as
TMEM166
, Beclin-1, cleaved casepase-3 and
Bcl-2
/Bax. The study found that
TMEM166
siRNA treatment significantly reduced the mortality rate, cerebral edema, neurobehavioral deficits, and BBB disruption as measured by Evan's blue assay following MCAO injury. Immunohistochemical staining and western blotting analysis demonstrated an increased expressions of
TMEM166
, Beclin-1, LC3, cleaved casepase-3 and
Bcl-2
/Bax in the infarcted areas. This study suggests that
TMEM166
induces autophagy and apoptosis may in fact play a significant role in cell death following MCAO injury and its mediation may be through the crosstalk of
Bcl-2
. By blocking the activity of
TMEM166
using siRNA, we were able to prevent the cell loss that occured following cerebral ischemia injury. This translated into a preservation of functional integrity and an improvement in mortality.
...
PMID:Transmembrane protein 166 regulates autophagic and apoptotic activities following focal cerebral ischemic injury in rats. 2222 58